- A severe case of psoriasis treated with brodalumab after failure of previous biologic therapy - case report2022 | Third Faculty of Medicine
- Successful treatment of recalcitrant gluteal hidradenitis suppurativa with brodalumab after anti-TNF failure2020 | Third Faculty of Medicine
- Management of Moderate to Severe Plaque Psoriasis with Brodalumab in Daily Practice: Real-World Evidence from the LIBERO Study in the Czech Republic2024 | First Faculty of Medicine, Faculty of Medicine in Pilsen, Third Faculty of Medicine
- Efficacy, safety, and drug survival of patients with psoriasis treated with IL-17 inhibitors - brodalumab, ixekizumab, and secukinumab: real-world data from the Czech Republic BIOREP registry2022 | First Faculty of Medicine, Faculty of Medicine in Pilsen, Third Faculty of Medicine, Central Library of Charles University
- 2 Brodalumab po selhání jiné biologické léčby2021 | Third Faculty of Medicine
- Current Approach to Modern Treatment of Psoriasis - Updated Guidelines of ČDS JEP for Targeted Treatment of Severe Chronic Psoriasis2019 | First Faculty of Medicine, Faculty of Medicine in Pilsen, Third Faculty of Medicine
- Inhibition of IL-17 - a new approach in the biological treatment of spondyloarthritides2017 | First Faculty of Medicine
- IL-17 inhibitors in psoriasis treatment2022 | Third Faculty of Medicine
- Efficacy of switches within the class of IL-17 inhibitors: An analysis of data from the Czech nationwide registry of psoriatic patients receiving biological/targeted therapy (BIOREP)2022 | First Faculty of Medicine, Faculty of Medicine in Pilsen, Third Faculty of Medicine, Central Library of Charles University
- Drug Survival of IL-12/23, IL-17 and IL-23 Inhibitors for Psoriasis Treatment: A Retrospective Multi-Country, Multicentric Cohort Study2021 | Third Faculty of Medicine
- Drug Survival of Interleukin (IL)-17 and IL-23 Inhibitors for the Treatment of Psoriasis: A Retrospective Multi-country, Multicentric Cohort Study2022 | Third Faculty of Medicine